GenSpera Launches National Investor Relations Program

SAN ANTONIO and NEW YORK, March 30, 2015 /PRNewswire/ -- GenSpera Inc. GNSZ announced today the selection of PCG Advisory Group (PCG) to launch a comprehensive investor relations initiative for the oncology-focused drug development company. Led by Jeff Ramson, founder and chief executive officer, the PCG team will also be directed by three senior members: Kirin Smith, COO and managing director of investor relations; Jeffrey Hart, managing director of market intelligence; and Sean Leous, CCO. The team will be supported by Carl Mauch, science analyst.

"We are on the cusp of a major step forward for GenSpera, and PCG will be instrumental in ensuring the investor relations community remains informed about our work," said Craig Dionne, Ph.D., chief executive officer of GenSpera. "We selected a group that has the experience and understands the questions investors and partners want answered, whether they are in the United States, Asia or Europe. PCG is known for its ability to communicate to a wide audience in a clear, articulate manner."

"GenSpera is a unique company, developing the prodrugs of the future," said Ramson. "We are launching our initiative with a Tri-State area roadshow, April 1-3, and a Dallas and Houston roadshow, April 6 and 7. We will introduce Craig to brokers, high-net worth individuals, family office managers and accredited investors who have a strong interest in biotechnology. The team at PCG is currently implementing an extended investor roadshow calendar for Craig, commencing when he returns from China in the latter part of April. We are looking at key investment markets, including: Atlanta, Boston, Chicago, Denver, Florida (which consists of several key high-net worth target areas), Los Angeles, San Francisco and Toronto. We look forward to a long and successful relationship with GenSpera."

GenSpera recently presented positive Phase II study results for the company's lead investigational agent mipsagargin in treating hepatocellular carcinoma (HCC) at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif., demonstrating a proof of concept for its intellectual property. GenSpera also recently announced a strategic partnership with a global supplier for the manufacture of the key ingredient in mipsagargin.

About GenSpera
GenSpera Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. GenSpera's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit www.genspera.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

About PCG Advisory Group
Founded in 2008, PCG Advisory Group is dedicated to the delivery of top tier capital markets advisory services, strategic and tactical digital and social media communications and cutting edge media and public relations for public and privately held companies.

The team at PCG has extensive experience with life sciences and healthcare, high technology, metals and mining, financial services and emerging growth companies from around the globe.

PCG's Capital Markets Advisory Services include overall investor strategy development to increase and leverage investor awareness, visibility and credibility. PCG's Social and Digital Media services include leveraging social and professional digital media sites to effectively and accurately communicate client stories. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail and institutional investors using proprietary techniques, search engine optimization, online marketing, website development and our proprietary and extensive distribution network. PCG's Media and Public Relations services are a strategic and integral component of all Corporate Communications. The media and public relations team works with print, broadcast, online news sites and bloggers to communicate the best client story at the right time. PCG also has the capabilities to assist a company during a merger, acquisition or crisis.

Communicating the client's story accurately and effectively is tantamount to maximizing exposure to its current and potential stakeholders. For additional information on PCG, visit www.pcgadvisory.com.

Cautionary Statement Regarding Forward Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of GenSpera's technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera's proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genspera-launches-national-investor-relations-program-300057108.html

SOURCE GenSpera, Inc.